ArcticZymes Technologies — Investor Presentation 2017

May 31, 2017

AngloNordic Conference May 2017

Biotec Pharmacon ASA

• Listed on Oslo Stock exchange (ticker: biotec)
• Headquarter in Tromsø, Norway
• 45 employees
• Annual turnover of NOK 70M (2016)
• 25 years of history in two technology platforms:
• Immunomodulatory Beta-glucans
• Enzymes for molecular research and diagnostics

Immunomodulatory Beta-Glucans

Beta-Glucan product portfolio

M-Glucan®- Animal health

• Experienced solid growth in demand from 2015 to 2016 and into Q1 2017
• Close to production capacity of supplier. Collaborating to expand production capacity to meet expected further increase
• May 2016, signed an additional 2 year supply agreement with an indicated value of MNOK 20

M -Gard ® - Nutrition product

• Cleared in arbitration means right to sell products world wide
• Utilize production capacity in existing facilities = about NOK 20M revenue potential
• A number of commercial activities within consumer health generating leads and opportunities
• Strategy to sell directly to production and trade mark owners makes us very competitive
• Will launch a web -shop for sales of M -Gard® to consumers in 2017

Cancer adjuvant

• Memorial Sloan Kettering Cancer Center (MSKCC) expand their Neuroblastoma study to 145 patients due to positive results. 120 patients are enrolled
• MSKCC plan to publish results in the second half of 2017
• Biotec and MSKCC are discussing how to move forward
• Exploring other areas where SBG can used as an adjuvant
• In general, experience increased awareness of combination treatments and use of adjuvants

Woulgan®, part of the solution

• Woulgan with active beta-glucan reactivates the healing process

• Focused on stall wounds

• Registered in EU as a class 3 product with strong claims

Stalled wounds, a global problem

• 6,5 millioner chronic wounds in the US(~1/3 of market)

• GBP 20 billion used on treament of wounds in the US

• It's expected that 1-2% of the population will experience a chronic wound

9

Enzymes for molecular research and diagnostics

Commercialising the Arctic Uniqueness

Leveraging uniqueness

Arctic Bioprospecting

• Driven by University of Tromsø (UiT) • Large biobank of novel enzymes

Discovery

• Identifying commercially attractive & novel enzymes • Engineering & formulation to enhance desired features
• Product Development & Manufacturing • Cost efficient manufacturing • Scalability & customisation

Commercialisation

• B2B product offering => Early access
• Support for application development (integration into customer workflows)

Products and segments

Products and Pipeline Segments

Molecular research

Molecular diagnostics

Other markets

Contact:

CEO

Svein W.F. Lien sl@biotec.no Phone: +47 922 89 323

CFO Børge Sørvoll bso@biotec.no Phone: +47 952 90 187